TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amplia Therapeutics ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics has announced that its ACCENT trial, which evaluates the combination of its FAK inhibitor narmafotinib with standard chemotherapies gemcitabine and Abraxane, has achieved a key milestone with 15 confirmed partial responses in patients with advanced pancreatic cancer. This demonstrates the superiority of the combination therapy over chemotherapy alone, potentially enhancing the company’s positioning in the oncology market. The trial’s success could have significant implications for stakeholders, as it suggests a promising new treatment option for a highly aggressive cancer type.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focusing on the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company has a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer, and FAK is also a significant target in chronic diseases like idiopathic pulmonary fibrosis.
Average Trading Volume: 387,584
Technical Sentiment Signal: Sell
Current Market Cap: A$21.34M
Find detailed analytics on ATX stock on TipRanks’ Stock Analysis page.